NCT00393861View on ClinicalTrials.gov

Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

October 31, 2012

Study Completion Date

November 30, 2014

Conditions
Neoplasms, Germ Cell and Embryonal
Interventions
DRUG

Bevacizumab and Oxaliplatin

Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes

Trial Locations (2)

19104

University of Pennsylvania:Abramson Cancer Center, Philadelphia

46202

Indiana Univeristy Cancer Center, Indianapolis

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Indiana University

OTHER